Galena Biopharma announces notice of allowance of U.S. patent for NeuVax™ (nelipepimut-S)
Galena Biopharma committed to development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced the USPTO issued a Notice of Allowance for an additional U.S. patent application covering multiple uses of NeuVax™ (nelipepimut-S). February 08, 2016